Work

A first-in-human phase 1 dose-escalation study of the oral HIF-2α inhibitor JMKX003948 in patients with renal cell carcinoma.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.4544

Authors: Xieqiao Yan, Xinan Sheng, Zhihong Chi, Chuanliang Cui, Lu Si, Yan Kong, Bin Lian, Lili Mao, Juan Li, Huayan Xu, Xiaowen Wu, Huihui Xiang, Lina Gu, Lei Yang, Jun Guo

Institution: Peking University Cancer Hospital

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162522676

Cites:

Cited by:

Related to: